Gerry Connolly
The Public Record
Gerry Edward Connolly is a member of the United States House of Representatives, representing Virginia's 11th congressional district since 2009. A member of the Democratic Party, Connolly has focused on various issues including government accountability, environmental protection, and healthcare reform. He has served on several committees, including the House Committee on Oversight and Reform, where he has been involved in investigations and legislation related to federal oversight and transparency.
We can't have people exercising illegal options, right? We all want to be within the law.
There is a role for Federal Government, there is a role for government regulation. It protects people.
The new rule would impose an eventual ban on existing nonnavigable houseboats and floating homes in 30 years.
I'm with you all the way, Mr. Johnson, on the assertion that nobody has any permanent squatting rights on public land.
I think it's important, in an era where all too often, we hear rhetoric about the hobnail booted government on our necks, and government can't do anything right, that's not true.
Don't get too carried away with that smaller government thing, because that's not how your region advanced.
Most are familiar with the TVA, which, by the way, was a great success story of government investment in an underperforming region during very difficult economic times.
I mean--and I--this is not a new question, because I remember--unless I'm smoking something, but at this very room, this very subcommittee, we've looked at a figure of estimates of around $50- to $60 billion.
I would love to see a--sort of a spitball strategy that says--okay. In theory, we know we can't ever get to zero.
So I'm trying to look at the whole pie. That pie is $136 billion, 43 percent are documentation error. So what percent do we think are fraud?
I'm tired of paying prescription drug companies and drug manufacturers and device companies to treak these issues.
I propose that maybe we need a price protection program for public health drugs, and that we need to decide a public formulary.
There's one message for us here in the public and quite another for investors.
You should foresee that just continuing as we continue to maximize the EpiPen franchise.
You virtually have a monopoly and you've used it to your advantage, but, unfortunately, it's at the expense of people who need it.





